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Abstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved 
raltegravir for treatment of human immunodeﬁ  ciency virus (HIV)-1 infection in combination 
with other antiretroviral agents in treatment-experienced adult patients who have evidence of 
viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is ﬁ  rst 
in a novel class of antiretroviral drugs known as integrase inhibitors. It has demonstrated potent 
anti HIV activity in both antiretroviral treatment-naïve and experienced patients. The most com-
mon adverse events reported with raltegravir during phase 2 and 3 clinical trials were diarrhea, 
nausea, and headache. Laboratory abnormalities include mild elevations in liver transaminases 
and creatine phosphokinase.
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Introduction
A paradigm shift has occurred in the management of heavily treatment-experienced 
patients as a result of the introduction of new and potent antiretroviral drugs and our 
improved understanding of how best to incorporate these agents into a new treatment 
regimen. Thus, virological suppression has become an attainable goal for many of 
these patients. However, tolerability, adherence, and broad cross resistance within each 
class of antiretroviral drugs remain an issue and continue to limit the efﬁ  cacy of current 
treatment options. Therefore, there is a continued need for new classes of drugs.
The integrase inhibitors target a viral enzyme that catalyses an essential process 
in the replication cycle of HIV – the insertion of HIV-1 proviral DNA into the host’s 
cellular genome. Thus, they represent one of the most promising targets in the HIV 
life-cycle for therapeutic intervention. Raltegravir is a new, ﬁ  rst-in-class drug in the 
class of integrase inhibitors and has demonstrated impressive potency in both treatment-
naïve and treatment experienced patients. This review summarizes available data on 
the clinical safety and efﬁ  cacy of raltegravir as well as the general characteristics of 
the drug. Data for this review were obtained from papers published in the English 
language identiﬁ  ed by searches of Medline, Current Contents, and references from 
relevant articles. The search terms used were “raltegravir”, “integrase inhibitors”, and 
“MK-0518”. The review also includes data presented at major HIV-related meetings 
including Conference on Retroviruses and Opportunistic Infections, International AIDS 
Society Conference on HIV Pathogenesis and Treatment, Infectious Diseases Society 
of America annual meeting, International Congress on Drug Therapy in HIV Infection, 
Interscience Conference on Antimicrobial Agents and Chemotherapy, and International 
AIDS Conference. Data were also obtained from the Antiviral drugs Advisory Com-
mittee brieﬁ  ng Document, submitted by the manufacturer to the FDA.
Structure and mechanism of action
The integration of HIV-1 proviral DNA into the host cell genome is an obligate replica-
tion step of the HIV life cycle and occurs in three steps (LaFemina et al 1992; Hazuda 
et al 2000; Craigie et al 2001). Following reverse transcription of the viral RNA into a Therapeutics and Clinical Risk Management 2008:4(2) 494
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double-stranded DNA copy, the viral DNA remains associated 
with a “preintegration complex” that contains both viral 
and cellular proteins including the viral integrase protein. 
The integration of the viral DNA into the host chromosome 
is subsequently achieved through a series of DNA cutting 
and joining reactions. First, two nucleotides are removed 
from each 3'-end of the viral DNA, a process termed 3'-end 
processing. In the second step, termed DNA strand transfer, 
the processed viral DNA ends are inserted or joined into the 
host DNA. The HIV-1 integrase catalyses these ﬁ  rst two steps 
of integration. In the third step, cellular enzymes repair the 
single gaps in the DNA chain by removing the two unpaired 
nucleotides at the 5'-ends of the viral DNA.
The development of raltegravir evolved from the dis-
covery of speciﬁ  c compounds that contained a distinct β 
diketo acid (DKA) moiety with potent and selective inhibi-
tory activity against the strand transfer step of integration 
(Hazuda et al 1999, 2005; Espeseth et al 2000; Pais et al 
2002; Embrey et al 2005). Substitution of the 1,3-DKA 
moiety by 8-hydroxy-(1,6) naphthyridine led to the synthesis 
of more metabolically stable candidates represented by the 
naphthyridine carboxamide compounds. Further modiﬁ  -
cations of these compounds led to the synthesis of a new 
naphthyridine derivative, raltegravir (formerly known as 
L-900612 and MK-0518) and its emergence as a candidate for 





Raltegravir is rapidly absorbed with a bioavailability of at least 
32%. With twice daily dosing, pharmacokinetic steady state 
is achieved within approximately the ﬁ  rst 2 days of dosing 
(Isentress 2007; Isentress FDA Brieﬁ  ng Document 2007; Kas-
sahun et al 2006). Raltegravir is approximately 83% bound to 
human plasma proteins. The apparent terminal t½ of raltegravir 
in humans is approximately 9 hours with a shorter α-phase 
half-life (∼1hour) accounting for much of the AUC. This and 
its elimination proﬁ  le support the use of a twice-daily dosing 
regimen for raltegravir. High fat meal slows the rate of absorp-
tion of raltegravir but also increases its exposure (area under the 
curve, AUC). Following a single 400 mg dose administration of 
raltegravir with high fat meal, the time to reaching maximum 
plasma concentration (Cmax ) was delayed by 7.5 hours and 
the Cmax itself was decreased by 34%. However, the AUC was 
increased by approximately 19%. Therefore, raltegravir may 
be administered without regard to food. The major mechanism 
of clearance of raltegravir in human beings is metabolism via 
UGT1A1-mediated glucuronidation (Isentress 2007; Isentress 
FDA Brieﬁ  ng Document 2007; Kassahun et al 2006, 2007). 
After an oral administration of radiolabeled raltegravir, approxi-
mately 51% was excreted in feces while 31% was excreted in 
urine. No adjustment of dosing is necessary for age, gender, body 
mass index, HIV infection status, hepatic and renal function 
(Isentress 2007; Isentress FDA Brieﬁ  ng Document 2007).
Interactions
Raltegravir is metabolized by glucuronidation. At a concen-
tration up to 100 µM, raltegravir does not inhibit or induce 
nor is it a substrate of cytochrome P450 enzymes. Thus, it 
is expected that interactions with drugs metabolized by the 
CYP450 system, including protease inhibitors and non-
nucleoside reverse transcriptase inhibitors, are unlikely 
(Isentress FDA Brieﬁ  ng Document 2007).
Atazanavir is a known inhibitor of UGT1A1, the primary 
pathway of clearance of raltegravir, and was selected to 
assess the greatest potential for increases in raltegravir phar-
macokinetics (Mistry et al 2007). Both atazanavir alone and 
in combination with ritonavir were investigated in phase 1 
studies. Additional data on this interaction was also obtained 
from the phase 2 population PK data. In those studies, ralte-
gravir plasma levels were increased when coadministered 
with atazanavir, consistent with inhibition of UGT1A1. The 
increases, however, were on the whole modest (30%–70% 
increases in AUC) and not considered clinically meaningful. 
Additionally, concomitant use of raltegravir and atazanavir 
was well tolerated in the phase 2 and phase 3 studies. Based 
on these data, atazanavir may be coadministered with ralte-
gravir without adjustment in the dose of raltegravir.
Tenofovir is known to signiﬁ  cantly affect the pharmaco-
kinetics of other antiretroviral agents through mechanisms 
that are not entirely clear. Phase 1 and 2 studies that include 
coadministration of raltegravir and tenofovir concluded that 
there is no clinically meaningful interaction and the two drugs 
can be coadministered without dose adjustment (Wenning 
et al 2006a). Similarly, the interaction of raltegravir with 
efavirenz, etravirine and tipranavir with low dose of rito-
navir was studied and found not to be clinically meaningful 
(Iwamoto et al 2006a; Wenning et al 2006b). Rifampin is 
a potent inducer of cytochrome P450. Coadministration 
of rifampin with raltegravir decreased raltegravir 12-hour 
concentration by an average of 61% (Iwamoto et al 2006b). 
The drop in raltegravir level with potent cytochrome P450 
inducers is most likely clinically signiﬁ  cant and caution 
should be used if rifampin or similar potent CYP450 inducers Therapeutics and Clinical Risk Management 2008:4(2) 495
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such as phenytoin and phenobarbital are coadministered with 
raltegravir (Kassahun et al 2006).
Coadministration of oral contraceptives (Ortho Tri-
Cyclen or generic equivalent) with raltegravir for 21 days 
did not substantially alter plasma exposure levels of either 
ethinyl estradiol or norelgestromin in healthy female subjects 
(Anderson et al 2007).
Antiviral activity
In vitro studies
Raltegravir demonstrated antiviral activity in cell culture 
against a broad panel of HIV isolates, including primary iso-
lates from a variety of subtypes, isolates resistant to protease 
inhibitors (PIs), nucleoside reverse transcriptase inhibitors 
(NRTIs), and non-nucleoside reverse transcriptase inhibi-
tors (NNRTIs), and even against simian immunodeﬁ  ciency 
virus (SIV) (Miller et al 2006). It inhibited the strand transfer 
activity of puriﬁ  ed HIV-1 integrase in vitro with an IC50 of 
2–7 nM. Raltegravir was also  1000-fold more selective for 
HIV-1 integrase as compared with other phosphoryltransfer-
ases tested, including the polymerase and RNase H activities 
of HIV-1 reverse transcriptase and the human polymerases 
α, β, and γ.
Clinical studies
Phase 2 clinical trials
Study 004
Study 004 was a multicenter, double-blind, randomized, 
placebo-controlled, 2-part, dose-ranging study of raltegravir in 
antiretroviral naïve HIV-infected adults with a plasma HIV-1 
RNA level of 5000 copies/mL or greater and a CD4+ T-cell 
count of at least 100 cells/mm3 at screening. The ﬁ  rst part of 
the study was a 10-day monotherapy phase that compared 
4 doses of raltegravir (100, 200, 400, and 600 mg) to placebo, 
each given twice daily, in 35 patients (Markowitz et al 2006). 
Patients were stratiﬁ  ed at entry by initial plasma HIV-1 RNA 
level (  or  50,000 copies/mL). Baseline plasma HIV-1 
RNA levels were comparable among all 5 groups with mean 
values ranging from 4.53 to 4.97 log10 copies/mL. All 
35 patients completed the 10-day study. The antiviral response 
was similar among all raltegravir groups (mean decreases in 
log10 HIV RNA level of 1.93, 1.98, 1.66, and 2.16 copies/
mL 100, 200, 400, and 600 mg twice daily, respectively) 
and was signiﬁ  cantly greater compared with placebo (mean 
decreases in log10 HIV RNA −0.17; p   0.001). At least 
half of the patients in each raltegravir dose group achieved 
an HIV RNA level  400 copies/mL by day 10. There were 
no differences in the slope of HIV RNA decline between 
patients with HIV RNA level   or  50,000 copies/mL 
at study entry. Drug-related clinical adverse events were 
reported in 10 patients (8 among the 4 raltegravir treatment 
groups and 2 patients in the placebo group). These were mild 
or moderate in intensity. There were no serious adverse events 
and no discontinuations because of adverse experiences. 
One patient in the 100-mg raltegravir group experienced a 
grade 1 increase in alanine transferase (ALT) on day 5 which 
resolved by day 10 without interruption of therapy.
The second part of study 004 enrolled 198 antiretroviral 
treatment-naive patients (including 30 patients from the 
ﬁ  rst part of study 004) and compared the safety and efﬁ  cacy 
of the 4 different doses of raltegravir described above to 
that of efavirenz, each drug combined with tenofovir and 
lamivudine (Markowitz et al 2007). Baseline characteristics 
were in general comparable across all study arms. Mean 
baseline HIV-1RNA values were 4.6–4.8 log10 copies/mL 
across all groups. Mean baseline CD4 cell counts ranged 
from 271 to 314 cells/mm3. All participants had documented 
genotypic susceptibility to TDF, 3TC, and EFV. At 48 weeks, 
virologic efficacy was comparable between raltegravir 
and efavirenz with all 5 treatment arms demonstrating a 
greater than 2.2 log10 decline in HIV-1 RNA. Virologic 
failure occurred at similar rates (3%). Signiﬁ  cantly more 
patients in the raltegravir arms achieved HIV-1 RNA  50 
copies/mL at week 4 and 8 than patients in the EFV arm but 
these differences were no longer statistically signiﬁ  cant by 
week 12 and responses remained similar to week 48. Mean 
increases from baseline in CD4+ T cell count exceeded 
100 cells/mm3 in all arms. Adverse events were uncommon, 
were mild to moderate in nature, and were generally similar 
across all treatment groups.
Study 005
Study 005 was a multicenter, double-blind, randomized, 
placebo-controlled, dose-ranging study that assessed the 
safety and efﬁ  cacy of raltegravir when added to optimized 
background regimens in 178 antiretroviral experienced HIV-
infected adults with a plasma HIV-1 RNA level above 5000 
copies/mL and a CD4+ T-cell count of at least 50 cells/mm3 
at screening (Grinsztejn et al 2007). Participants were also 
required to be on stable antiretroviral therapy for more than 
3 months and have documented genotypic or phenotypic 
resistance to at least one non-nucleoside reverse transcriptase 
inhibitor, one nucleoside reverse transcriptase inhibitor, and 
one protease inhibitor. Each patient’s optimized background 
regimen was selected by investigators prior to randomization 
based on results from all available genotypic and phenotypic Therapeutics and Clinical Risk Management 2008:4(2) 496
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resistance tests as well as the patient’s antiretroviral treatment 
history. Patients were randomized in a 1:1:1:1 ratio to one 
of three doses of raltegravir (200 mg, 400 mg, or 600 mg) 
or placebo twice daily. At randomization, patients were also 
stratiﬁ  ed by enfuvirtide use and by the degree of resistance 
to PIs at study entry. The primary endpoints were the change 
in HIV-1 RNA from baseline at week 24 and safety. The 
demographic and other baseline characteristics of the patients 
were comparable in all four groups. At 24 weeks, virologic 
and immunologic treatment outcomes were better for each 
raltegravir arm compared to the placebo arm (p   0.0001). 
Table 1. The treatment differences between raltegravir and 
placebo groups were consistent across all phenotypic and 
genotypic sensitivity scores (PSS and GSS). GSS and PSS 
refer to the number of drugs in the regimen to which the virus 
is deemed to be sensitive according to the baseline genotype 
or phenotype. For example, a genotypic sensitivity score of 
0 means that participants received no other active drugs in 
addition to raltegravir or placebo). The use of enfuvirtide 
in the optimized background regimen was associated with 
improved outcomes with both raltegravir and placebo. Ralte-
gravir at all doses had a comparable safety proﬁ  le to that of 
placebo. There were no apparent dose-related toxicities.
Phase 3 clinical trials
On the basis of the data from study 004 and 005 the dose 
of 400 mg twice daily of raltegravir was selected for phase 
III studies.
BENCHMRK
BENCHMRK-1 and -2 (study 018 and 019) are two parallel, 
identical, ongoing phase III double-blind, placebo-controlled 
studies, that are evaluating the efﬁ  cacy and safety of raltegravir 
plus an optimized background regimen in patients with triple 
class resistant HIV-1 virus (Cooper et al 2007; Steigbigel 
et al 2007). BENCHMRK 1 was conducted in Europe, Asia 
and the Paciﬁ  c, and Peru. BENCHMRK 2 was conducted 
in North, Central, and South America. Eligible participants 
were those failing antiretroviral therapy with triple antiretro-
viral class resistance and were randomized 2:1 to raltegravir 
400 mg twice daily or placebo. Participants were required to 
have plasma HIV-1 RNA level above 1000 copies/mL and 
documented genotypic or phenotypic resistance to at least one 
non-nucleoside reverse transcriptase inhibitor, one nucleoside 
reverse transcriptase inhibitor, and one protease inhibitor. An 
optimized background therapy (OBT) was selected by the 
treating physicians. Select investigational drugs (eg, daruna-
vir) were permitted to be part of OBT. The demographic and 
other baseline characteristics of the patients were compa-
rable between the raltegravir and placebo arms in each study 
(Table 2). The primary endpoint was the proportion of patients 
that achieved HIV-1 RNA  400 copies/mL at week 16. Addi-
tional efﬁ  cacy endpoints included percentage of patients with 
HIV RNA  50 copies/mL as well as change from baseline 
in HIV-1 RNA levels and CD4 cell counts. At 16 weeks, the 
raltegravir arm was found to be superior in its antiretroviral 
effect compared to the placebo arm (Table 3). Superior efﬁ  cacy 
of the raltegravir arms over placebo was maintained regard-
less of baseline CD4 count, HIV-1 RNA values as well as 
genotypic and phenotypic scores in the OBT. Adverse events 
were similar between groups. 24-week combined results of the 
BENCHMRK studies conﬁ  rm that the superior efﬁ  cacy of the 
raltegravir arms was sustained (Kumar et al 2007) (Table 4). 
Analysis of these 24-week combined results also provided 
an insight into differences in treatment outcome based on the 
drugs used in the OBT (Table 5). While the raltegravir arms 
remained more effective than the placebo arms regardless of 
the composition of the OBT, differences in treatment outcome 
were smaller if darunavir and enfurvitide were used together 
in patients not previously exposed to them.
Table 1 Study 005: 24-week results
Raltegravira 200 mg  Raltegravira 400 mg  Raltegravira 600 mg  Placeboa
n 43 45 45 45
Change from baseline in HIV-1 RNA 
(log10 copies/mL)
–1.80 –1.87 –1.84 –0.35
Proportion of patients with HIV-1 RNA 
 400 Copies/mL 
69.8% 71.1% 71.1% 15.6%
Proportion of patients with HIV-1 RNA 
 50 copies/mL 
65.1% 55.6% 66.7% 13.3%
Change from baseline in CD4 cell count 
(cells/µL)
62.9 112.8 94.1 5.4
aPlus optimized background regimen.Therapeutics and Clinical Risk Management 2008:4(2) 497
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Safety
Raltegravir safety data are obtained primarily from the phase 
2 and 3 studies of raltegravir described above – study 004, 
005, and the BENCHMRK studies. Study 004 in particular 
is an important source of safety information on raltegravir 
since participants in both arms of the study received the exact 
same regimen (tenofovir plus lamivudine) with the excep-
tion of the two drugs that were being compared, raltegravir 
and efavirenz.
In study 004, the most frequently reported clinical adverse 
events in the raltegravir groups (all doses combined) regard-
less of causality were: diarrhea (18.8%), nausea (18.1%), 
Table 2 Selected baseline characteristics BENCHMRK-1 and -2 trials
BENCHMRK-1 BENCHMRK-2
Raltegravir Placebo Raltegravir Placebo
n 232 118 230 119
Age 46.1 43.7 45.3 46.5
Male 84.1% 87.3% 91.3% 89.9%
Baseline CD4 count (mean) 156.4 152.8 146.4 163.2
Baseline HIV-1 RNA (mean) 
log10 copies/mL
4.6 4.5 4.7 4.7
AIDS diagnosis 93.5% 89.8% 90.9% 92.4%
Prior antiretroviral use in 
years (median)
10.6 10.3 9.6 10.1
Number of antiretrovirals 
used in the past
12 12 12 12
Enfurvitidea in optimized 
background regimen
37.9% 36.4% 37.8% 38.7%
Resistance to  PIs 97% 94.9% 96.5% 95.8%
Derived from Isentress FDA Brieﬁ  ng Document (2007).
aIncludes those already enfuvirtide experienced.
Abbreviation: PIs, protease inhibitors.
Table 3 BENCHMRK-1 and 2: treatment outcome at week 16
BENCHMRK-1 BENCHMRK-2
Raltegravir Placebo Raltegravir Placebo
n 232 118 230 119
Proportion of patients with 
HIV-1 RNA  400 copies/mL
76.7% 40.7% 77% 42.9%
Proportion of patients with 
HIV-1 RNA  50 copies/mL
60.8% 33.1% 61.7% 36.1%
Proportion of patients with  1 
log decline in HIV-1 RNA
84.9% 41.5% 82.6% 50.4%
Mean change in HIV-1 RNA 
(log10 copies/mL) from 
baseline 
−1.85 −0.78 −1.92 −1.06
Mean change in CD4 count 
(cells/mm3) from baseline 
+82.7 +31.3 +85.1 +39.7
Virologic failure – non 
respondera
1.7% 37.3% 3.9% 28.6%
Virologic failure – reboundb 12.1% 16.1% 12.6% 19.3%
Derived from Isentress FDA Brieﬁ  ng Document (2007).
anon-responders did not achieve  1.0 log10 HIV RNA reduction or  400 HIV RNA copies/mL by week 16.
bviral rebound was deﬁ  ned as: (a) HIV RNA  400 copies/mL (on 2 consecutive measurements at least 1 week apart) after initial response with HIV RNA  400 copies/mL, 
or (b)  1.0 log10 increase in HIV RNA above nadir level (on 2 consecutive measurements at least 1 week apart).Therapeutics and Clinical Risk Management 2008:4(2) 498
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upper respiratory infection (16.9%), headache (16.3%), 
dizziness (11.9%), nasopharyngitis (10.6%), and insomnia 
(10.6%). The most frequently reported (incidence  10%) 
drug-related clinical adverse experience in the raltegravir 
treatment groups (all doses combined) was nausea (11.3%). 
There was no apparent association between the frequency 
of clinical adverse events (drug-related or not) and increas-
ing raltegravir dose. Elevations of alanine aminotransferase 
(ALT) or aspartate aminotransferase (AST) were reported in 
3.8% of patients in the raltegravir treatment groups (all doses 
combined) compared to 5.3% of patients in the efavirenz 
group. Of note, raltegravir, in contrast to efavirenz, had no 
appreciable effect on total cholesterol, LDL cholesterol, or 
triglycerides (Kassahun et al 2007; Markowitz et al 2007).
Understanding safety data from studies in treatment-
experienced patients can be a challenge because of the 
additional confounding factors including differences in the 
optimized background regimens and advanced stage of HIV 
disease. In study 005 as well as the 2 BENCHMRK stud-
ies, adverse events were generally balanced between the 
raltegravir arms and the placebo arms (Cooper et al 2007; 
Grinsztejn et al 2007; Kassahun et al 2007; Steigbigel et al 
2007). Serious adverse events were reported in 10.7% of 
raltegravir recipients versus 12.8% of patients receiving 
placebo. The most common drug-related clinical adverse 
events were diarrhea (3.7% vs 3.5%), nausea (2.2% vs 3.2%), 
and headache (2.2% vs 1.4%). The proportions of laboratory 
adverse events were comparable between the raltegravir and 
the placebo group. However, three laboratory adverse events 
were reported more frequently in patients in the raltegravir 
groups compared to patients in the placebo groups: eleva-
tions of ALT (4.5% vs 2.1%); elevations of AST (4.3% vs 
2.5%); elevations of creatine phosphokinase (CPK) (3.2% 
vs 0.7%). As regards the aminotransferase elevations, they 
were usually transient and did not generally lead to study or 
drug discontinuation. In patients with hepatitis B and/or C co-
infection, increases in ALT and AST did not differ between 
raltegravir and placebo groups: 5.1% and 7.7%, respectively, 
for the raltegravir group and 5.1% and 5.1%, respectively, 
for the placebo group. As regards the elevations of creatine 
phosphokinase, many of these elevations were transient and 
some were thought to be related to physical exercise. No 
patient discontinued therapy due to increased CPK.
Nine deaths were reported in the BENCHMRK studies: 
6 from the raltegravir group (1.2%) and 3 from the placebo 
group (1.1%). In general, these deaths were related to severe 
opportunistic infection and/or malignancy. None of these 
deaths has been determined to be drug-related (Kassahun 
et al 2007).
Malignancies were reported at a higher rate in patients 
on raltegravir in the phase 2 and 3 studies compared to 
patients on a comparator arm: 19 (2.5%) vs 5 (1.5%). 
However, the difference between the two groups was not 
sustained when the rates of malignancies were adjusted 
for the patient years of exposure to the study drug (Kas-
sahun et al 2007). Thus, the patient-year adjusted rates 
of malignancies per 100 patient-years were 2.32 in the 
raltegravir arms and 1.92 in the comparator groups with a 
relative risk of 1.209 (95% conﬁ  dence interval 0.44, 4.14). 
The malignancies reported include Kaposi’s sarcoma, non-
Hodgkin’s lymphoma, anogenital squamous cell cancer, 
rectal cancer, hepatocellular cancer, and non-melanoma 
skin cancer. Eight of the 19 cancers in the raltegravir were 
recurrent; the remaining 11 occurred within  3 months 
of enrollment. The median CD4 cell count of the patients 
receiving raltegravir who ultimately developed a malig-
nancy was 122 cells/mm3. All patients with malignancy 
also had a history of AIDS.
Resistance
Current knowledge regarding HIV resistance to raltegravir 
is incomplete and evolving. In vitro studies have identiﬁ  ed 
Table 5 Combined BENCHMRK 1 and 2, 24-week results – response 
according to drugs in optimized background therapy
 BENCHMRK  Placebo
  1 and 2
n 448  230
Proportion of patients with HIV-1   65%  35%
RNA  50 copies/mL
Proportion of patients with ﬁ  rst   80%  74%
time darunavir and  enfurvitide use 
with HIV-1 RNA  50 copies/mL
Proportion of patients with ﬁ  rst time   68%  48%
darunavir but no enfurvitide use with 
HIV-1 RNA  50 copies/mL
Proportion of patients with ﬁ  rst time   82%  50%
enfuvirtide but no darunavir use with
HIV-1 RNA  50 copies/mL
Table 4 Combined BENCHMRK 1 and 2, 24-week treatment 
outcome
  BENCHMRK 1 and 2  Placebo
n 448  230
Proportion of patients with   65%  35%
HIV-1 RNA  50 copies/mL 
Mean change in CD4 count   +84  +37
(cells/mm3) from baseline Therapeutics and Clinical Risk Management 2008:4(2) 499
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a series of speciﬁ  c amino acid changes in the gene coding 
for the integrase enzyme that occur over time during culture 
in increasing raltegravir concentrations. The ﬁ  rst change 
observed was Q148K followed by E138A and G140A with 
acquisition of additional mutations with higher drug concen-
trations. Introduction of these mutations (Q148K, E138A/
Q148K, and E138A/G140A/Q148K) into a wild-type virus 
resulted in a substantial fold-shift (46–508 fold) in raltegravir 
IC50. An additional effect of these mutations was a reduction 
in viral replication (Kassahun et al 2007).
Studies of treatment-emergent resistance to raltegravir 
in the phase 2 and 3 clinical trials have provided further 
insight (Hazuda et al 2007; Kassahun et al 2007). Most 
patients experiencing virologic failure while receiving a 
raltegravir-containing regimen will fail with viruses that dis-
play integrase mutations that confer resistance to raltegravir 
(in particular if they are treatment-experienced patients). It 
appears that there are two distinct pathways of resistance 
one involving amino acid residue 148 (Q148H, Q148K, or 
Q148R) the other involving N155H. These mutations confer 
10- to 25-fold, respectively, decreased susceptibility to ralte-
gravir. Additional secondary mutations such as L74M, E92Q, 
T97A, E138K, G140S, V151I, G163G/R, and D232D/N 
may also be present in raltegravir virologic failures. These 
secondary mutations by themselves contribute only in a 
modest way to resistance to raltegravir. However, when 
combined with either of the two primary mutations, they lead 
to substantial further decreases in raltegravir susceptibility. 
Further analysis of virologic failure samples from the 005 
study as well as from a phase II trial of elvitegravir, another 
integrase inhibitor, has indicated that there may be substantial 
cross resistance between these two drugs (Hazuda et al 2007; 
McColl et al 2007). A recent case report appears to corrobo-
rate these ﬁ  ndings (DeJesus et al 2007). Two patients partici-
pating in the phase 2 elvitegravir phase II GS-US-183-0105 
trial were allowed to switch from elvitegravir/ritonavir to 
raltegravir with the same background regimen for one week 
after experiencing virologic failure. One patient had A91Q, 
Q95Q/K, T97T/A, N155H at virologic failure. The second 
had H51Y, E138E/K, P145P/S, S147G, Q148R at virologic 
failure. No signiﬁ  cant reductions in HIV-1 RNA for either 
patient were noted after 1 week of raltegravir substitution. 
These results led to the termination of the pilot study under 
which this evaluation was conducted.
Conclusion
Raltegravir, a novel integrase inhibitor has demonstrated 
impressive antiviral potency in heavily treatment-experienced 
patients as well as in patients naïve to antiretroviral therapy. 
These impressive results render raltegravir a viable option 
for treating patients of varying treatment experience but the 
optimal role of raltegravir in the sequencing of antiretroviral 
therapy, and the optimal antiretroviral agents to combine it 
with remain to be deﬁ  ned. The availability of raltegravir, 
together with other recently introduced new antiretroviral 
drugs, has the potential to alter the prevailing treatment 
paradigm of combining two NRTIs with a PI or an NNRTI 
as the corner stone of highly active antiretroviral therapy.
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